Dublin, Feb. 27, 2020 (GLOBE NEWSWIRE) -- The "Small Molecule API Contract Manufacturer Quality Benchmarking (5th Edition)" report has been added to ResearchAndMarkets.com's offering. Small Molecule ...

The "U.S. Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report by Stage Type (Preclinical, Clinical, Commercial), Customer Type, Therapeutic Area, Region, and Segment ...

Small molecule API are highly beneficial in the diagnosis, treatment and prevention of a vast range of disorders and is useful as research tool to study biological function and develop new therapeutic ...

Wilmington PharmaTech ("WPT"), a U.S.-based specialty contract research, development and manufacturing organization (CRDMO) focused on complex custom small molecule API, today announced that it has ...

DUBLIN--(BUSINESS WIRE)--The "Small Molecule API Contract Manufacturer Quality Benchmarking (2nd edition)" report has been added to Research and Markets' offering. As pharmaceutical and ...

TEL AVIV, Israel--(BUSINESS WIRE)--Teva announced today its intention to divest its active-pharmaceutical ingredient (API) business, or "TAPI". TAPI is a global leader in the small-molecule API ...

This month, the Joe Biden administration awarded $14 million to the API Innovation Center, a Saint Louis–based nonprofit that aims to remedy supply chain problems for active pharmaceutical ingredients ...

(MENAFN- EIN Presswire) EINPresswire/ -- The small molecule CMO/CDMO sector is experiencing robust growth fueled by evolving pharmaceutical industry needs and strategic outsourcing trends. As drug ...

Small molecule API are highly beneficial in the diagnosis, treatment and prevention of a vast range of disorders and is useful as research tool to study biological function and develop new therapeutic ...

TEDA TIANJIN, China--(BUSINESS WIRE)-- Asymchem Laboratories (Tianjin) Co., Ltd. (Stock Code 002821.SZ/6821.HK) announced today that it will operate the former Pfizer U.K. small molecule API pilot ...

The MarketWatch News Department was not involved in the creation of this content. The global industry was valued at US$ 38.9 Bn in 2022 and is expected to register a CAGR of 7.1% from 2023 to 2031.

Teva (NYSE:TEVA) plans to divest its active-pharmaceutical ingredient (API) business as part of its Pivot to Growth strategy to focus on its core business strengths. "The intent to divest TAPI will ...